0/100
Not Eligible
27/100
Expensive Valuation
19/100
Technically Bearish
Strength
4
Weakness
9
Opportunity
0
Threats
0
Market Cap (Cr)
PE Ratio
Price to Book Ratio
RSI
Net Profit Margin
Closure of Trading Window
Closure of Trading Window
AGM On 30.09.2024
AGM on 30.09.2024
Board Meeting Outcome for Outcome Of Board Meeting Held On 06.09.2024 - 8Th Annual General Meeting T
Outcome of Board Meeting held on 06.09.2024 - Reappointment of Independent Directors Secretarial & Internal Auditors and regarding 8th AGM of the Company
Reg. 34 (1) Annual Report.
Annual Report for FY 2023-24
Intimation Of Submission Of Application To BSE For Reclassification From Promoter Category To Public
Intimation of submission of application to BSE for reclassification from Promoter to Public Category
Regulation 30 - Submission Of Resignation Letters Of Directors Dated 19.07.2024
Submission of resignation letters of Directors dated 19.07.2024 pursuant to Regulation 30 of SEBI (LODR) Regulations 2015
Approval Of Board For Reclassification Of 2 Promoters To Public Category
Approval of Board for reclassification of 2 Promoters to Public Category
Approval Of Board For Reclassification Of 2 Promoters To Public Category
Approval of Board for reclassification of 2 Promoters to Public Category
Results For The Period Ended 31.03.2024
Results for the period ended 31.03.2024
Board Meeting Outcome for Outcome Of Board Meeting Held On 19.07.2024
Outcome of Board Meeting held on 19.07.2024
Board Meeting Intimation for Intimation Regarding Postponement Of Board Meeting To 19.07.2024 For Ap
Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/07/2024 inter alia to consider and approve the Standalone and Consolidated financial results of the Company for the half year and year ended 31.03.2024 and... More>
Board Meeting Intimation for Approval Of Financial Results For The Half Year And Year Ended 31.03.20
Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/07/2024 inter alia to consider and approve the financial results for the half year and year ended 31.03.2024
Compliance Certificate Under Regulation 40(9)
Compliance Certificate under Regulation 40(9)
Reg. 34 (1) Annual Report.
Annual Report for FY 2021-22
Compliance Certificate Under Regulation 7(3)
Compliance Certificate under Regulation 7(3)
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
Receipt of order worth Rs. 1.2 Cr for technical studies
Appointment of Company Secretary and Compliance Officer
Appointment of CS and Compliance Officer w.e.f 01.04.2024